Welcome to our dedicated page for Connect Biopharma Holdings news (Ticker: CNTB), a resource for investors and traders seeking the latest updates and insights on Connect Biopharma Holdings stock.
Connect Biopharma Holdings Limited reports clinical and corporate developments for a clinical-stage biopharmaceutical company focused on inflammatory diseases. Its principal program is rademikibart, an antibody designed to target interleukin-4-receptor alpha, with company updates centered on asthma, chronic obstructive pulmonary disease and moderate-to-severe atopic dermatitis.
Recurring news includes rademikibart clinical data, Seabreeze STAT asthma and COPD study updates, Data Monitoring Committee and regulatory-related disclosures, partner activity involving Simcere in China, financial results, financing activity, investor conference participation and governance matters.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that Dr. Zheng Wei and CFO Steven Chan will participate in a fireside chat at the Jefferies Healthcare Conference on June 10, 2022, at 10:30 am ET. A live webcast will be available on the Company’s Investor Relations page, with a replay post-event. Connect Biopharma focuses on therapies for chronic inflammatory diseases, leveraging T cell-driven research, including its lead product CBP-201 for treating atopic dermatitis and asthma. The company is advancing multiple candidates targeting T cell biology in the U.S. and China.
Connect Biopharma (Nasdaq: CNTB) will present data on CBP-201 at the Society for Investigative Dermatology Annual Conference from May 18-21, 2022. Preclinical experiments show CBP-201 effectively reduces Th2-driven inflammation biomarkers and exhibits a stronger binding affinity compared to dupilumab. The antibody targets interleukin-4 receptor alpha (IL-4Rα), with promising results from a Phase 2b clinical trial indicating potential for treating moderate-to-severe atopic dermatitis. The ongoing pivotal trial in China further supports its clinical significance.
CANbridge Pharmaceuticals has appointed Dr. Pauline Li as Senior Vice President of Clinical Development and Operations, effective May 8. Dr. Li previously held leadership roles at Connect Biopharma, overseeing significant clinical trial achievements. With a robust background in drug development across various markets, her experience is expected to enhance CANbridge's clinical programs targeting rare diseases and oncology. The company has three approved drugs and a pipeline of 11 assets, reflecting its commitment to addressing unmet medical needs.
Connect Biopharma (Nasdaq: CNTB) announced Phase 2 trial results for CBP-307, a treatment for ulcerative colitis. The 0.2 mg dosage showed a numerical decrease in the adapted Mayo Score at Week 12, but did not reach statistical significance (p=0.103). However, it achieved significant clinical remission rates compared to placebo: 28.3% vs. 9.6% (p=0.016). Lymphocyte count reductions confirmed pharmacodynamic activity. CBP-307 was generally well tolerated, with a 66% incidence of drug-related adverse events. The company is considering partnerships for further development while advancing lead candidate CBP-201.
Connect Biopharma reported financial results for the year ended December 31, 2021, highlighting a cash balance of RMB 1,706.9 million (USD 267.7 million). The company advanced its clinical development projects, announcing a Phase 3 trial for CBP-201 in atopic dermatitis set to start in H2 2022 and completion of enrollment for CBP-307's Phase 2 trial in ulcerative colitis. Research and development expenses surged to RMB 518.0 million (USD 81.2 million), contributing to a net loss of RMB 1,306.8 million (USD 205.0 million) for the year.
Connect Biopharma (NASDAQ: CNTB) has appointed Dr. Chin Lee as Chief Medical Officer, effective March 1, 2022, aiming to enhance its clinical pipeline for inflammatory diseases. Dr. Lee brings over 15 years of experience from Theravance Biopharma and Genentech, focusing on drug development in immunology. His expertise is expected to propel the advancement of their therapeutic candidates, including CBP-201 and CBP-307, which target conditions like asthma and ulcerative colitis. The company is committed to global clinical development and improving patient outcomes.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) announced that CEO Dr. Zheng Wei will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 16, 2022, at 4:20 PM ET. The chat will be accessible via a webcast on the company's Investor Relations page. Connect Biopharma is focused on developing therapies for chronic inflammatory diseases, with lead candidates including CBP-201 for atopic dermatitis and asthma, and CBP-307 for ulcerative colitis and Crohn’s disease.
Connect Biopharma has reported significant results from its Phase 2b clinical trial for CBP-201, a treatment for moderate-to-severe atopic dermatitis. The trial achieved both primary and key secondary endpoints, showing substantial improvements in skin clearance, disease severity, and itch compared to placebo. Patients with higher baseline disease severity experienced greater efficacy, indicating a competitive safety profile. CBP-201 features a differentiated Q4W dosing schedule, enhancing its appeal in the market.
Connect Biopharma (Nasdaq: CNTB) reported positive results from its Phase 2b trial of CBP-201 for moderate-to-severe atopic dermatitis, demonstrating significant improvements in skin clearance and a favorable safety profile compared to placebo. The trial met all primary and key secondary endpoints, showing strong efficacy for both Q2W and Q4W dosing regimens. A Phase 3 trial is set to begin in the second half of 2022. Further analysis indicated that patients with higher baseline disease severity experienced greater treatment benefits. Key safety metrics revealed low incidence of adverse events.
Connect Biopharma Holdings Limited (Nasdaq: CNTB) will host a conference call and webcast on January 5, 2022, at 8:30 AM Eastern Time to discuss detailed data from its Phase 2b trial of CBP-201 for moderate-to-severe atopic dermatitis. The trial aims to evaluate the safety and efficacy of CBP-201, an antibody targeting IL-4Rα. This call is a significant step for Connect Biopharma as they continue to advance their pipeline of therapies for chronic inflammatory diseases. Interested parties can access the call via a provided link or by phone.